Brain natriuretic peptide-guided therapy in the inpatient management of decompensated heart failure

References

• Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics: 2011 update: a report from the American Heart Association. Circulation123(4), e18–e209 (2011).
   PubMed Web of Science ®Google Scholar
• Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur. Heart J.12, 315–321 (1991).
   PubMed Web of Science ®Google Scholar
• Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA261, 884–888 (1989).
   PubMed Web of Science ®Google Scholar
• Atkinson A, Colburn W, DeGruttola V et al. Biomarkers and surrogate end points: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69, 89–95 (2001).
   PubMed Web of Science ®Google Scholar
• Bozkurt B, Mann DL. Use of biomarkers in the management of heart failure. Are we there yet? Circulation107, 1231–1233 (2003).
   PubMed Web of Science ®Google Scholar
• Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation115, 949–952 (2007).
   PubMed Web of Science ®Google Scholar
• Clerico A, Vittorini S, Passino C, Emdin M. New and emerging biomarkers of heart failure. Crit. Rev. Clin. Lab. Sci.46, 107–128 (2009).
   PubMed Web of Science ®Google Scholar
• Jortani SA, Prabhu SD, Valdes R. Strategies for developing biomarkers of heart failure. Clin. Chem.50, 265–278 (2004).
   Google Scholar
• Taub PR, Gabbai-Saldate P, Maisel A. Biomarkers of heart failure. Congest. Heart Fail.16(1 Suppl.), S19–S24 (2010).
   Google Scholar
• Novo G, Amoroso GR, Fazio G et al. Biomarkers in heart failure. Front. Biosci.14, 2484–2493 (2009).
   Google Scholar
• Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am. J. Physiol. Heart Circ. Physiol.301, H12–H20 (2011).
   PubMed Web of Science ®Google Scholar
• Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J. Cardiol.57, 131–140 (2011).
   PubMed Web of Science ®Google Scholar
• Emdin M, Passino C, Clerico A. Natriuretic peptide assays revisited. Do we need proB-type natriuretic peptide? J. Am. Coll. Cardiol.57, 1396–1398 (2011).
   Google Scholar
• MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet353, 2001–2007 (1999).
   PubMed Web of Science ®Google Scholar
• CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet353, 9–13 (1999).
   PubMed Web of Science ®Google Scholar
• CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med.316, 1429–1435 (1987).
   PubMed Web of Science ®Google Scholar
• SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med.325, 293–302 (1991).
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med.341, 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Lenzen MJ, Boersma E, Reimer WJ et al. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur. Heart J.26, 2706–2713 (2005).
   PubMedGoogle Scholar
• Hauptman PJ, Swindle JP, Masoudi FA, Burroughs TE. Underutilization of beta-blockers in patients undergoing implantable cardioverter-defibrillator and cardiac resynchronization procedures. Circ. Cardiovasc. Qual. Outcomes3, 204–211 (2010).
   PubMedGoogle Scholar
• Krittayaphong R, Boonyasirinant T, Saiviroonporn P, Thanapiboonpol P, Nakyen S, Udompunturak S. Correlation between NT-pro BNP levels and left ventricular wall stress, sphericity index and extent of myocardial damage: a magnetic resonance imaging study. J. Card. Fail.14, 687–694 (2008).
   Google Scholar
• Haug C, Metzele A, Kochs M, Hombach V, Grünert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin. Cardiol.16, 553–557 (1993).
   PubMedGoogle Scholar
• Richards AM, Crozier IG, Yandle TG, Espiner EA, Ikram H, Nicholls MG. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br. Heart J.69, 414–417 (1993).
   PubMedGoogle Scholar
• Yoshimura M, Yasue H, Okumura K et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation87, 464–469 (1993).
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Wada A, Maeda K et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J. Am. Coll. Cardiol.37, 1228–1233 (2001).
   PubMed Web of Science ®Google Scholar
• McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation100, 1056–1064 (1999).
   PubMed Web of Science ®Google Scholar
• Latini R, Masson S, Anand I et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Val-HeFT trial. Circulation106, 2454–2458 (2002).
   PubMed Web of Science ®Google Scholar
• Troughton RW, Richards AM, Yandle TG, Frampton CM, Nicholls MG. The effects of medications on circulating levels of cardiac natriuretic peptides. Ann. Med.39, 242–260 (2007).
   PubMed Web of Science ®Google Scholar
• Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med.347, 161–167 (2002).
   PubMed Web of Science ®Google Scholar
• Maisel A, Hollander JE, Guss D et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J. Am. Coll. Cardiol.44, 1328–1333 (2004).
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J. Am. Coll. Cardiol.49, 1943–1950 (2007).
   PubMed Web of Science ®Google Scholar
• Moe GW, Howlett J, Januzzi JL, Zowall H. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation115, 3103–3110 (2007).
   PubMed Web of Science ®Google Scholar
• Mueller C, Scholer A, Laule-Kilian K et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N. Engl. J. Med.350, 647–654 (2004).
   PubMed Web of Science ®Google Scholar
• Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet355, 1126–1130 (2000).
   PubMed Web of Science ®Google Scholar
• Jourdain P, Jondeau G, Funck F et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J. Am. Coll. Cardiol.49, 1733–1739 (2007).
   PubMed Web of Science ®Google Scholar
• Berger R, Moertl D, Peter S et al. N-terminal pro-B-type natriuretic peptide-guided intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J. Am. Coll. Cardiol.55, 645–653 (2010).
   PubMed Web of Science ®Google Scholar
• Felker GM, Hasselblad V, Hernandez AF et al. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am. Heart J.158, 422–430 (2009).
   PubMed Web of Science ®Google Scholar
• Lainchbury JG, Troughton RW, Strangman KM et al. N-terminal pro-B-type natriuretic peptide-guided treatment of chronic heart failure. J. Am. Coll. Cardiol.55, 53–60 (2010).
   Google Scholar
• Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch. Intern. Med.170, 507–514 (2010).
   PubMedGoogle Scholar
• Beck-da-Silva L, de Bold A, Fraser M, Williams K, Haddad H. BNP-guided therapy not better than expert’s clinical assessment for beta-blocker titration in patients with heart failure. Congest. Heart Fail.11, 248–253 (2005).
   Google Scholar
• Shah MR, Califf RM, Nohria A et al. STARBRITE: a randomized pilot trial of BNP-guided therapy in patients with advanced heart failure. Presented at: American Heart Association Scientific Sessions. Chicago, IL, USA, 12–15 November 2006.
   Google Scholar
• Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlstrom U. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NTproBNP-Guided Management of Heart Failure–SIGNAL-HF (Swedish Intervention study – Guidelines and NTproBNP Analysis in Heart Failure). Eur. J. Heart Fail.12, 1300–1308 (2010).
   PubMed Web of Science ®Google Scholar
• Pfisterer MP, Buser P, Rickli H et al.; TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA301, 383–392 (2009).
   PubMed Web of Science ®Google Scholar
• Eurlings LW, van Pol PE, Kok WE et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can Pro-Brain-Natriuretic Peptide Guided Therapy of Chronic Heart Failure Improve Heart Failure Morbidity and Mortality?) study. J. Am. Coll. Cardiol.56, 2090–2100 (2010).
   PubMed Web of Science ®Google Scholar
• Clerico A, Fontana M, Ripoli A et al. Clinical relevance of BNP measurement in the follow-up of patients with chronic heart failure. Adv. Clin. Chem.48, 163–179 (2009).
   PubMedGoogle Scholar
• Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E et al. N-terminal probrain natriuretic peptide (NTproBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur. J. Heart Fail.6, 301–308 (2004).
   PubMed Web of Science ®Google Scholar
• Di Somma S, Magrini L, Mazzone M et al. Decrease in NTproBNP plasma levels indicates clinical improvement of acute decompensated heart failure. Am. J. Emerg. Med.25, 335–339 (2007).
   PubMed Web of Science ®Google Scholar
• Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation110, 2168–2174 (2004).
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Lopez L, Zapico E et al. NTproBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. J. Card. Fail.11(Suppl. 5), S3–S8 (2005).
   PubMed Web of Science ®Google Scholar
• Cournot M, Leprince P, Destrac S et al. Usefulness of in-hospital change in B-type natriuretic peptide levels in predicting long-term outcome in elderly patients admitted for decompensated heart failure. Am. J. Geriatr. Cardiol.16(1), 8–14 (2007).
   Google Scholar
• Logeart D, Thabut G, Jourdain P et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J. Am. Coll. Cardiol.43, 635–641 (2004).
   PubMed Web of Science ®Google Scholar
• Valle R, Aspromonte N, Giovinazzo P et al. B-type natriuretic peptide-guided treatment for predicting outcome in patients hospitalized in sub-intensive care unit with acute heart failure. J. Cardiac Fail.14, 219–224 (2008).
   PubMed Web of Science ®Google Scholar
• Noveanu M, Breidthardt T, Potocki M et al. Direct comparison of serial B-type natriuretic peptide and NTproBNP levels for prediction of short- and long-term outcome in acute decompensated heart failure. Crit. Care15(1), R1 (2011).
   PubMed Web of Science ®Google Scholar
• Cournot M, Mourre F, Castel F et al. Optimization of the use of B-type natriuretic peptide levels for risk stratification at discharge in elderly patients with decompensated heart failure. Am. Heart J.155(6), 986–991 (2008).
   PubMed Web of Science ®Google Scholar
• Di Somma S, Magrini L, Pittoni V et al. In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED study. Crit. Care14(3), R116 (2010).
   Web of Science ®Google Scholar
• Bettencourt P, Januzzi J. Amino-terminal pro-B-type natriuretic peptide testing for inpatient monitoring and treatment guidance of acute destabilized heart failure. Am. J. Cardiol.101(1), A67–A71 (2008).
   PubMedGoogle Scholar
• Xue Y, Chan J, Sakariya S et al. Biomarker-guided treatment of congestive heart failure. Congest. Heart Fail.16(4 Suppl. 1), S62–S67 (2010).
   Google Scholar
• Emdin M, Vittorini S, Passino C et al. Old and new biomarkers of heart failure. Eur. J. Heart Fail.11, 331–335 (2009).
   Google Scholar
• Yin WH, Chen JW, Feng AN et al. Multimarker approach to risk stratification among patients with advanced chronic heart failure. Clin. Cardiol.30, 397–402 (2007).
   PubMed Web of Science ®Google Scholar
• Ishino M, Takeishi Y, Niizeki T, Watanabe T, Nitobe J, Miyamoto T. Risk stratification of chronic heart failure patients by multiple biomarkers: implications of BNP, H-FABP, and PTX3. Circ. J.72, 1800–1805 (2008).
   PubMed Web of Science ®Google Scholar
• Niizeki T, Takeishi Y, Kitahara T et al. Combination of conventional biomarkers for risk stratification in chronic heart failure. J. Cardiol.53, 179–187 (2009).
   PubMed Web of Science ®Google Scholar
• Tziakas D, Chalikias G, Stakos D et al. Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events. Eur. J. Cardiovasc. Prev. Rehabil. doi:10.1097/HJR.0b013e32833ace76 (2010) (Epub ahead of print).
   Google Scholar
• Volpe M, Francia P, Tocci G et al. Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: a 15-year prospective follow-up study. Clin. Cardiol.33, 700–707 (2010).
   PubMed Web of Science ®Google Scholar
• Tang WH, Shrestha K, Troughton RW, Borowski AG, Klein AL. Integrating plasma high-sensitivity C-reactive protein and myeloperoxidase for risk prediction in chronic systolic heart failure. Congest. Heart Fail.17, 105–109 (2011).
   PubMedGoogle Scholar
• Gopal DJ, Iqbal MN, Maisel A. Updating the role of natriuretic peptide levels in cardiovascular disease. Postgrad. Med.123(6), 102–113 (2011).
   PubMed Web of Science ®Google Scholar